Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Regenaflex-K9 is a veterinary regenerative biologic therapy developed by Hilltop BioSciences specifically for canine soft tissue and joint conditions. It is formulated as a bioscaffold material containing growth factors, cytokines, microRNA, and exosomes derived from amniotic sources, which deliver a cell-signaling cascade to reduce inflammation, promote tissue healing, support reparative tissue ingrowth, and minimize scarring. Administered via intra-articular injection or topical flex-Gel, it targets lameness from osteoarthritis, tendon/ligament/muscle injuries, non-healing wounds, and acute/chronic inflammation, offering consistent dosing, room-temperature stability, and rapid reconstitution compared to variable biologics like PRP or stem cells. Preliminary data from blinded studies show positive outcomes in canine osteoarthritis, with case reports demonstrating full soundness post-treatment.[1][2][3][4][5][8]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Regenaflex-K9.